TY - JOUR
AU1 - Hara, Kenju
AU2 - Togashi, Masaru
AB - INTRODUCTIONOfatumumab, a human anti‐CD20 monoclonal antibody that selectively depletes B‐cells, has been approved in several countries worldwide for the treatment of relapsing forms of multiple sclerosis (MS).1,2 Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease characterized by the proliferation of joint synovial tissue, formation of pannus, and destruction of cartilage.3 Recent studies have shown evidence of an important role of B‐cells in the pathogenesis of RA and in the efficacy of B‐cell depletion therapy for RA.4,5 We report a case with both MS and refractory RA that was successfully treated with ofatumumab.CASE REPORTA 40‐year‐old woman with a 2‐month history of finger joint pain was diagnosed with RA based on increased C‐reactive protein levels and positive results for anti‐cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor (RF) at the rheumatic disease clinic. Although there was temporary improvement of her symptoms by the initial treatment with conventional synthetic disease‐modifying antirheumatic dugs (cs DMARDs), namely salazosulfapyridine (1000 mg/day), she had received more treatment with oral prednisolone (2.5–7.5 mg/day), iguratimod (50 mg/day), tacrolimus (3 mg/day), and methotrexate (MTX) (8–12 mg/week) along with development of disease activity (Figure 1). In this case, tumor necrosis factor–α (TNF‐α) blockers, which are known to develop demyelinating lesions, were not used.6 She was 
TI - Successful treatment of multiple sclerosis with refractory rheumatoid arthritis using ofatumumab: A case report
JF - Clinical and Experimental Neuroimmunology
DO - 10.1111/cen3.12780
DA - 2024-08-01
UR - https://www.deepdyve.com/lp/wiley/successful-treatment-of-multiple-sclerosis-with-refractory-rheumatoid-OFBQ5hNtBK
SP - 122
EP - 125
VL - 15
IS - 3
DP - DeepDyve
ER -